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Background: Although factors associated with the utilisation of bone density measurement (BDM) and
osteoporosis treatment have been regularly assessed in the US and Canada, they have not been effectively
analysed in European countries. This study assessed factors associated with the utilisation of BDM and osteoporosis
medication (OM) in Switzerland.
Methods: The Swiss Health Survey 2007 data included self-reported information on BDM and OM for women aged
40 years and older who were living in private households. Multivariable logistic regression analysis was used to
identify sociodemographic, socioeconomic, healthcare-related and osteoporosis risk factors associated with BDM
and OM utilisation.
Results: The lifetime prevalence of BDM was 25.6% (95% CI: 24.3-26.9%) for women aged 40 years and older. BDM
utilisation was associated with most sociodemographic factors, all the socioeconomic and healthcare-related factors,
and with major osteoporosis risk factors analysed. The prevalence of current OM was 7.8% (95% CI: 7.0-8.6%) and it
was associated with some sociodemographic and most healthcare-related factors but only with one socioeconomic
factor.
Conclusions: In Swiss women, ever having had a BDM and current OM were low and utilisation disparities exist
according to sociodemographic, socioeconomic and healthcare-related factors. This might foster further health
inequalities. The reasons for these findings should be addressed in further studies of the elderly women, including
those living in institutions.
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Health surveyBackground
In Switzerland and especially in women, the prevalence of
osteoporosis is high and expected to increase because of
the aging of the population [1]. In 2000, 316,000-348,000
women and men were estimated to have osteoporosis,
with this prevalence predicted to increase by 25% by 2020
(to 395,000-437,000 people) [2]. Osteoporosis-related
fragility fractures cause significant individual, societal and
economic burdens [2,3].
Fracture risk assessment, bone mineral density mea-
surement (BDM), and subsequent interventions (including* Correspondence: born.mph@bluewin.ch
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distribution, and reproduction in any mediummedical treatment) can reduce the risk of osteoporosis
and osteoporotic fractures [4-6].
General screening is not officially recommended in
Switzerland, although a “screen & treat” strategy against
osteoporosis was assessed to be cost-effective for women
aged 70 years and older [7,8]. In 2003, the Swiss Union
Against Osteoporosis (SVGO) recommended BDM for
diagnostic purposes after a fragility fracture, and it endorsed
screening prior to fractures when at least one major or two
minor risk factors were present [9]. In Switzerland, com-
pulsory health insurance covers BDM for diagnostic pur-
poses but not for screening purposes, except for individuals
with at least one major risk factor, such as long-termentral Ltd. This is an Open Access article distributed under the terms of the
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gonadism, hyperparathyroidism, or osteogenesis imper-
fecta [10].
In contrast to the SVGO, the Canadian Scientific
Advisory Council of Osteoporosis recommended routine
bone density screening for all individuals at age 65, and
screening prior to age 65 for those with certain risk
factors. In addition, BDM was recommended for diag-
nostic purposes after a fragility fracture [11]. Similarly,
the US Preventive Services Task Force advised women
aged 65 years and older or aged 60 years and older with
an increased osteoporosis risk to be routinely screened
for osteoporosis using dual-energy x-ray absorptiometry
(DXA) [12,13]. Despite the existence of these recom-
mendations, surveys among women in Canada and the
US showed that having had a BDM was associated with
sociodemographic factors and socioeconomic status, and
it was only weakly associated with osteoporosis risk
factors [14-16]. Similar associations were observed for
taking osteoporosis medication (OM), which was recom-
mended for postmenopausal women with low bone
density in Canada and the US [17,18].
Little is known about factors associated with BDM his-
tory and OM utilisation in Switzerland or other European
countries. However, the findings in Canada and the US led
us to hypothesise that similar disparities may exist in
Swiss women, even though BDM and OM are, with some
exceptions, reimbursed [10,19]. This hypothesis is also
supported by results of the Swiss Health Survey in 2002
showing, for example, variations in the utilisation of gene-
ral healthcare services and cancer screening modalities
according to sociodemographic and socioeconomic cha-
racteristics of the Swiss resident population [20].
The aim of our study was to describe the Swiss sit-
uation with regard to history of BDM and current OM
utilisation in Swiss women based on the most recent
Swiss Health Survey (SHS) data. Specifically, we sought to
assess whether BDM and OM utilisation in women vary
with respect to sociodemographic and socioeconomic fac-
tors, healthcare utilisation, and/or established risk factors
for osteoporosis and osteoporotic fractures that justify a
BDM according to SVGO recommendations.
Methods
Study design and data collection
The methods of the SHS 2007, including sampling,
weighting and adjustment for non-response are described
in detail elsewhere [21]. Briefly, the SHS 2007 was con-
ducted by the Swiss Federal Statistical Office (SFSO). The
survey data are representative for Swiss residents aged
15 years and older who lived in private households with a
registered landline phone in 2007. Institutionalised adults
(e.g., those in nursing homes, hospitals, prisons, and mon-
asteries), adults without a landline phone, individuals whoresided in Switzerland for 3 months or less and those who
did not speak German, French or Italian were, by design,
excluded [21,22].
A random sample was obtained by stratified selection
in two stages; in the first stage, households were ran-
domly selected in each canton with oversampling in 14
cantons, whereas in the second stage, one person was
randomly selected in each household. The sampling list
consisted of 30,179 addresses of households, of which
1,847 addresses were not valid. Of the remaining 28,332
households, 6,158 households were unavailable, and
3,414 persons refused to participate, resulting in a sam-
ple of 18,760 interviewed persons (response rate 66%).
The SHS participants were interviewed via a computer-
assisted phone interview (CATI) conducted by the Institute
MIS-Trend SA in Lausanne and Gümligen on behalf of the
SFSO. The SFSO constructed a weighting for each record
in the SHS to account for the oversampling in certain
cantons and for non-responses of households and indivi-
duals. The marginal distributions of the SHS respondents
weighted with respect to sex, age group, nationality, lan-
guage region and canton of residence were calibrated to
the distributions of the 2006 Swiss resident population,
excluding those living in institutions.
Questionnaire
The CATI questionnaire included close to 400 ques-
tions grouped in 69 domains, covering areas such as
sociodemographic and socioeconomic status, health
status, health-related behaviours and attitudes, and
health services utilisation [23].
Outcome variables
In contrast to the prior SHSs in 1992, 1997 and 2002,
the SHS 2007 contained questions pertinent to the his-
tory of BDM and OM utilisation.
All women aged 40 years and older were asked whether
they had ever had a BDM (yes or no). In addition, all
women older than 40 years (and not only those having
had a BDM) were asked how often they had taken medica-
tions against osteoporosis in the last 7 days (daily, several
times, about once or never) and in case of treatment, if
the medication had been prescribed by a physician (yes or
no). Whether a woman currently takes hormone replace-
ment therapy (HRT) was a separate question in the SHS.
Taking HRT was not classified as an OM. With this infor-
mation, the variable of physician prescribed OM in the
last 7 days (yes or no) was created.
Sociodemographic and socioeconomic factors
The sociodemographic variables assessed were age
(grouped into 40–49 years, 50–59 years, 60–69 years,
70–79 years, and ≥80 years), nationality (Swiss, Swiss
citizen with dual nationality, or other), language region
Born and Zwahlen BMC Musculoskeletal Disorders 2013, 14:10 Page 3 of 12
http://www.biomedcentral.com/1471-2474/14/10(German, French or Italian), region (Lake Geneva, Midland,
Northwest, Zurich, East, Central or Ticino) and residential
area (urban or rural). The socioeconomic variables
evaluated were type of hospitalisation insurance (public,
semiprivate or private), education level (compulsory,
secondary or tertiary) and equivalent per capita income
grouped in tertiles (lower, middle or upper).
The variables for region, residential area, education
level and equivalent per capita income were indexed,
calculated and supplied by the SFSO, and they are
described elsewhere [24].Health and healthcare-related factors
The healthcare-related factors assessed were number of
physician visits in the past 12 months (no visits, 1 visit,
2–6 visits, or >6 visits) and a gynaecologist check-up in
the last 12 months (yes or no). Self-assessed current
health status was obtained from the question “How is
your health in general?” with five response options from
“very bad” to “very good”. The question on self-assessed
health status is part of the “Minimum European Health
Module” (MEHM). The category “very good” was com-
bined with “good”, and “very bad” with “bad”. Whether
the individual had a health-oriented lifestyle (yes or no)
was derived from the question “How important is health
for you? You have here 3 different opinions. Please state
which one is closest to your own opinion: 1. I live with-
out taking care of possible consequences for my health.
2. Ideas on the maintenance of my health influence
my lifestyle. 3. Health-related considerations determine
mainly how I live.”
The respondents were coded to have a health-oriented
lifestyle if they gave answer 2 or 3. In addition, informa-
tion on having ever had a test for cancer in the absence
of symptoms was used to create a variable on cancer
screening ever performed (yes or no) with regard to
mammography and colon cancer screening. Further-
more, a variable describing the type of OM (none,
self-ordered, prescribed, or HRT) was constructed using
information on OM and HRT.Osteoporosis risk factors
The risk factors assessed were smoking (no, former or
not daily, or yes), daily tobacco consumption (none, 0–9
cigarettes, or ≥10 cigarettes), daily alcohol intake (none,
0–30 g, or >30 g) [6], underweight defined as body mass
index below 20 kg/m2 (yes or no) [6] and a history of
falls in the past 12 months (yes or no). The question on
falls was restricted to individuals aged 60 years and
older. Risk factors and their levels were defined taking
the FRAX calculation tool into account [6].
Level of physical activity (inactive, partially active,
or active) was included as protective factor. Thesecategories of physical activity were defined by the SFSO
as described elsewhere [24].
Statistical analysis
All analyses were weighted using the record weightings as
provided by the SFSO [21]. Survey commands (svy prefix)
of the statistical software Stata version 11.2 (Stata Corp,
College Station, Texas, US.) were used to perform the
weighted analyses.
For each variable of interest, the number of respon-
dents in each group, the (weighted) percentages of the
population in each group and the (weighted) percentages
of the population with the outcome of interest per group
were calculated. The significance of intergroup diffe-
rences was tested using the Pearson γ2-test (significance
level p<0.05).
The crude associations of variables of interest with
history of BDM or current OM were first evaluated
using univariable logistic regression analyses. To adjust
for confounders and to identify variables independently
associated with the outcome of interest, multivariable
logistic regression analyses were performed. Based on
the findings in the US and in Canada, three distinct
regression models were fitted; the first two models
included either sociodemographic covariates (age, region,
residential area) or socioeconomic covariates (education
level, per capita income, type of hospitalisation insurance),
and the third model adjusted for both groups (age, region,
residential area, education level, per capita income, hos-
pitalisation insurance type). The significance of asso-
ciations was examined using the Wald test (significance
level p<0.05).
The reference groups were the lowest level for the
ordered variables, the group with the highest number of
observations for the not-ordered categorical variables
and the level without the corresponding characteristic of
interest for the dichotomous variables. For age, the refe-
rence group was those aged 50–59 years. Ethical appro-
val was not required for this analysis of data, which are
available to research institutions according to the ordi-
nance on federal statistical monitoring activities and
surveys [25].
Results
Bone density measurement utilisation in women
Of the 7,052 female respondents aged 40 years and
older, 327 were excluded due to missing information
on BDM utilisation, leaving 6,725 women for analysis
(95.4%).
Lifetime prevalence of BDM
In 2007, 25.6% (95% CI: 24.3-26.9%) of female residents
aged 40 years and older had performed a BDM at least
once (Table 1). BDM prevalence was highest in the
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years age group (5.8%). It was highest in Ticino (32.0%)
and lowest in the Central region (17.8%), and it was
higher in urban areas (26.7%). Additionally, utilisation
rate was highest in the Italian-speaking region (31.4%),
which corresponds approximately to the Ticino, and
lowest in the German-speaking region (23.8%). Further-
more, ever having had a BDM was higher for women
with a higher income (29.8%), for women with private
hospitalisation insurance (36.6%) and for those with
more doctor visits in the past year. In addition it was
higher (33.7%) in those who had ever undergone a breast
or colon cancer screen.Factors associated with BDM utilisation
Most of the sociodemographic factors (age, language
region, region, and nationality), all the socioeconomic
factors (education level, income, and hospitalisation
insurance type) and all the healthcare-related factors
(number of doctor visits, gynaecologist check-up, cancer
screening ever performed, health-oriented lifestyle, and
self-assessed health) including OM showed statistically
significant associations with BDM utilisation after adjus-
ting for sociodemographic and socioeconomic factors,
but only few of the assessed osteoporosis risk factors
(underweight, physical activity level, and history of falls)
did (Table 1).
Lifetime BDM prevalence increased with age but
decreased slightly in those 80 years and older compared to
those aged 70–79 years. Women from the French-
speaking (OR 1.58) and the Italian-speaking (OR 1.56)
region more often had ever had a BDM than those from
the German-speaking region. Furthermore, Swiss dual
citizens more often had a BDM than did Swiss women
(OR 1.43). This association was only evident when adjust-
ing for sociodemographic factors. On the other hand, after
adjustment for sociodemographic and socioeconomic fac-
tors, residential area was no longer associated with BDM.
The associations of BDM prevalence with income and
hospitalisation insurance type remained statistically sig-
nificant even though the strength of the associations were
reduced when controlling for sociodemographic and
socioeconomic factors. In contrast to the crude results in
which no association was observed between education
level and BDM utilisation, the adjusted results showed
that women with a secondary (OR 1.45) or tertiary (OR
1.44) education more often had a BDM than women with
only compulsory education. Furthermore, women with a
health-oriented lifestyle (OR 1.66) and those who had
already undergone a screen for breast or colon cancer
(OR 1.51) had a higher BDM prevalence. Similar associa-
tions were found for gynaecologist check-up (OR 1.79)
and number of doctor visits.With regard to osteoporosis risk factors, lifetime
BDM prevalence was no longer associated with smok-
ing after adjustment for sociodemographic factors. On
the other hand, only in the adjusted analyses, under-
weight women (OR 1.34) and women with a history of
falls (OR 1.30) – and thus those with elevated osteopor-
osis and osteoporotic fracture risk – had more often
undergone a BDM. Women with a higher physical acti-
vity level and thus a decreased osteoporosis risk how-
ever were also more likely to have had a BDM than
were inactive women (OR 1.27).
Osteoporosis medication
Of the 7,052 women older than 40 years, 216 were
excluded due to missing answers regarding OM in the
last 7 days, leaving 6,836 women for analysis (96.9%).
Prevalence of current OM medication
In 2007, 7.8% (95% CI: 7.0-8.6%) of female Swiss resi-
dents older than 40 years reported having taken pre-
scribed OM (not including HRT) in the 7 days prior to
the interview (Table 2). OM prevalence increased with
age and was highest in the 70–79 years age group
(17.7%) and lowest in the 40–49 years age group (1.5%).
The prevalence was highest in the French-speaking
region of Switzerland (9.3%). OM prevalence was higher
in less educated women and in women with private hos-
pitalisation insurance (10.3%). Similarly, higher propor-
tions were observed in women with more doctor visits
in the past year and in women who had ever undergone
a breast or colon cancer screen (9.0%).
Factors associated with prescribed OM utilisation
Most of the healthcare-related factors (number of doctor
visits, gynaecologist check-up, BDM ever performed,
and self-assessed health) showed a statistically significant
association with OM when controlling for sociodemo-
graphic and socioeconomic factors, but only few of the
sociodemographic factors (age, and region) and only one
socioeconomic factor (hospitalisation insurance type)
did (Table 2): Prescribed OM prevalence was much
higher in women having ever had a BDM (OR 9.87),
although OM can be taken even without having per-
formed a BDM, and prevalence increased with number
of physician visits in the past year. In addition, pre-
scribed OM utilisation was higher in those having had a
gynaecologist check- up in the last 12 months (OR 1.61)
after adjustment for sociodemographic factors, while no
association was observed in the crude results.
On the other hand and in contrast to the crude
association, education level and breast or colon cancer
screening were no longer associated with medication
when adjusting for sociodemographic factors.
Table 1 BDM in women according to sociodemographic, socioeconomic, risk and healthcare-related factors
BDM Samplea Population Proportion with BDM Unadjusted model Adjusted modelb
Ever performed N % (95% CI) % (95% CI) crude OR (95% CI) adjusted OR (95% CI)
Total 6,725 100.0% 25.6% (24.3-26.9%)
Sociodemographic factors
Age group p=0.0000 p=0.0000 p=0.0000
40-49 years 1,760 31.1% (29.7-32.6%) 5.8% (4.6-7.3%) 0.19 (0.14-0.25) 0.21 (0.16-0.29)
50-59 years 1,536 24.9% (23.6-26.3%) 24.8% (22.2-27.5%) 1.00 (ref.) 1.00 (ref.)
60-69 years 1,629 21.5% (20.4-22.8%) 41.8% (38.8-44.8%) 2.18 (1.80-2.63) 2.48 (2.02-3.03)
70-79 years 1,195 14.8% (13.9-15.9%) 41.8% (38.4-45.4%) 2.18 (1.78-2.67) 2.70 (2.16-3.38)
≥80 years 605 7.6% (6.9-8.3%) 32.0% (27.5-36.8%) 1.43 (1.10-1.85) 1.78 (1.34-2.37)
mean age (years) 58.5 (58.2-58.9)
Nationality p=0.1109 p=0.0916 p=0.0074
Swiss citizen 5,502 78.3% (76.9-79.6%) 25.5% (24.2-27.0%) 1.00 (ref.) 1.00 (ref.)
Swiss dual citizen 712 10.1% (9.3-11.0%) 29.2% (25.4-33.4%) 1.20 (0.98-1.48) 1.43 (1.12-1.83)
others 510 11.6% (10.5-12.9%) 22.6% (18.3-27.5%) 0.85 (0.65-1.12) 1.32 (0.96-1.83)
unknown 1
Language region p=0.0000 p=0.0000 p=0.0000
German 4,148 72.8% (72.0-73.5%) 23.8% (22.3-25.4%) 1.00 (ref.) 1.00 (ref.)
French 1,965 22.1% (21.5-22.8%) 30.0% (27.6-32.6%) 1.37 (1.18-1.59) 1.58 (1.34-1.87)
Italian 612 5.1% (4.8-5.4%) 31.4% (27.3-35.8%) 1.46 (1.18-1.81) 1.56 (1.20-2.03)
Region p=0.0000 p=0.0000 p=0.0000
Lake Geneva 1,190 17.2% (16.6-17.8%) 30.0% (27.0-33.1%) 1.29 (1.06-1.58) 1.37 (1.09-1.72)
Midland 1,750 23.0% (22.2-23.7%) 24.8% (22.4-27.5%) 1.00 (ref.) 1.00 (ref.)
Northwest 752 14.9% (14.3-15.5%) 28.8% (25.2-32.6%) 1.22 (0.97-1.53) 1.13 (0.86-1.46)
Zurich 891 17.8% (17.2-18.5%) 24.0% (21.0-27.3%) 0.95 (0.76-1.19) 0.87 (0.68-1.12)
East 698 13.0% (12.4-13.6%) 23.1% (19.4-27.2%) 0.91 (0.70-1.17) 0.90 (0.68-1.21)
Central 839 9.3% (8.9-9.7%) 17.8% (14.9-21.1%) 0.65 (0.51-0.84) 0.65 (0.49-0.86)
Ticino 605 4.9% (4.6-5.1%) 32.0% (27.9-36.3%) 1.42 (1.12-1.80) 1.44 (1.09-1.92)
Residential area p=0.0035 p=0.0036 p=0.2215
urban 4,734 74.4% (73.2-75.6%) 26.7% (25.2-28.3%) 1.00 (ref.) 1.00 (ref.)
rural 1,991 25.6% (24.4-26.8%) 22.4% (20.0-24.9%) 0.79 (0.67-0.93) 0.89 (0.74-1.07)
Socioeconomic factors
Education level p=0.0905 p=0.0926 p=0.0041
compulsory 1,438 18.8% (17.7-20.1%) 24.3% (21.5-27.2%) 1.00 (ref.) 1.00 (ref.)
secondary 4,108 62.8% (61.3-64.3%) 26.7% (25.1-28.4%) 1.14 (0.95-1.36) 1.45 (1.16-1.81)
tertiary 1,179 18.3% (17.2-19.6%) 23.3% (20.5-26.3%) 0.95 (0.76-1.19) 1.44 (1.08-1.92)
Income per capita p=0.0000 p=0.0000 p=0.0271
lower tertile 2,058 32.4% (30.9-33.9%) 19.8% (17.7-22.0%) 1.00 (ref.) 1.00 (ref.)
middle tertile 2,121 35.2% (33.7-36.8%) 26.5% (24.3-28.8%) 1.46 (1.22-1.75) 1.10 (0.90-1.34)
upper tertile 2,073 32.3% (30.9-33.8%) 29.8% (27.5-32.3%) 1.72 (1.44-2.06) 1.32 (1.07-1.63)
unknown 473
mean income
(CHF per month)
4023 (3945-4101)
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Table 1 BDM in women according to sociodemographic, socioeconomic, risk and healthcare-related factors (Continued)
Hospitalisation
insurance p=0.0000 p=0.0000 p=0.0001
public 3,899 60.8% (59.3-62.3%) 21.5% (20.0-23.1%) 1.00 (ref.) 1.00 (ref.)
semiprivate 1,785 27.9% (26.6-29.4%) 30.9% (28.3-33.5%) 1.63 (1.40-1.90) 1.42 (1.19-1.70)
private 774 11.3% (10.4-12.2%) 36.6% (32.6-40.9%) 2.11 (1.72-2.58) 1.45 (1.15-1.83)
unknown 267
Healthcare-related factors and medication
Osteoporosis
medicationc in
the last 7 days p=0.0000 p=0.0000 p=0.0000
none 5,316 82.5% (81.3-83.6%) 20.5% (19.3-21.9%) 1.00 (ref.) 1.00 (ref.)
self-ordered 24 0.3% (0.2-0.4%) 43.7% (23.5-66.3%) 3.00 (1.18-7.63) 1.83 (0.63-5.32)
prescribed (not including HRT) 448 6.2% (5.6-7.0%) 79.9% (74.9-84.1%) 15.37 (11.45-20.63) 11.14 (8.07-15.39)
prescribed HRT 740 11.1% (10.1-12.1%) 38.0% (33.7-42.6%) 2.38 (1.93-2.92) 1.62 (1.28-2.06)
unknown 197
Number of doctor visits
in the past 12 months p=0.0000 p=0.0000 p=0.0000
no visits 889 13.6% (12.6-14.7%) 15.3% (12.6-18.4%) 1.00 (ref.) 1.00 (ref.)
1 visit 1,339 22.2% (20.9-23.5%) 18.7% (16.4-21.3%) 1.28 (0.97-1.69) 1.49 (1.09-2.04)
2-6 visits 3,166 47.5% (46.0-49.0%) 27.8% (26.0-29.8%) 2.14 (1.67-2.73) 2.09 (1.58-2.76)
>6 visits 1,167 16.7% (15.6-17.9%) 35.7% (32.3-39.2%) 3.07 (2.34-4.03) 2.87 (2.10-3.92)
unknown 164
mean number of visits 4.6 (4.3-4.8)
Gynaecologist check-up
in the last 12 months p=0.0043 p=0.0043 p=0.0000
no 3,618 51.8% (50.3-53.3%) 23.8% (22.1-25.5%) 1.00 (ref.) 1.00 (ref.)
yes 3,088 48.2% (46.7-49.7%) 27.5% (25.6-29.5%) 1.22 (1.06-1.39) 1.79 (1.51-2.12)
unknown 19
Cancer screening
(breast, colon) ever
performed p=0.0000 p=0.0000 p=0.0000
no 2,978 47.5% (46.0-49.0%) 16.7% (15.1-18.4%) 1.00 (ref.) 1.00 (ref.)
yes 3,710 52.5% (51.0-54.1%) 33.7% (31.9-35.7%) 2.55 (2.20-2.95) 1.51 (1.27-1.79)
unknown 37
Health-oriented lifestyle p=0.0242 p=0.0249 p=0.0050
no 379 7.2% (6.4-8.2%) 20.3% (15.7-25.7%) 1.00 (ref.) 1.00 (ref.)
yes 4,861 92.8% (91.9-93.6%) 26.8% (25.3-28.4%) 1.44 (1.05-1.98) 1.66 (1.16-2.35)
unknown 485
Self-assessed health state p=0.0000 p=0.0000 p=0.0000
(very) good 5,414 81.8% (80.6-82.9%) 23.0% (21.6-24.3%) 1.00 (ref.) 1.00 (ref.)
medium 1,010 14.2% (13.2-15.3%) 36.3% (32.6-40.2%) 1.92 (1.60-2.30) 1.66 (1.33-2.08)
(very) poor 297 3.9% (3.4-4.6%) 41.8% (34.7-49.4%) 2.42 (1.77-3.30) 2.76 (1.88-4.06)
unknown 4
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Table 1 BDM in women according to sociodemographic, socioeconomic, risk and healthcare-related factors (Continued)
Risk factors
Smoking (smoker) p=0.0006 p=0.0006 p=0.5451
no 3,806 56.8% (55.3-58.3%) 26.8% (25.1-28.5%) 1.00 (ref.) 1.00 (ref.)
ex (former or not daily) 1,692 25.5% (24.2-26.8%) 26.6% (24.2-29.3%) 0.99 (0.85-1.16) 1.09 (0.91-1.31)
yes 1,225 17.7% (16.6-19.0%) 20.2% (17.7-23.1%) 0.69 (0.57-0.84) 0.97 (0.77-1.22)
unknown 2
Tobacco consumption per day p=0.0000 p=0.0000 p=0.7711
none 5,328 79.9% (78.6-81.1%) 27.1% (25.6-28.6%) 1.00 (ref.) 1.00 (ref.)
0-9 cigarettes 541 8.0% (7.2-8.9%) 18.8% (15.2-23.0%) 0.62 (0.48-0.81) 0.91 (0.67-1.25)
≥10 cigarettes 836 12.1% (11.2-13.2%) 20.8% (17.6-24.3%) 0.71 (0.57-0.88) 0.93 (0.72-1.21)
unknown 20
Alcohol intake per day p=0.8684 p=0.8670 p=0.6308
none 2,443 34.7% (33.3-36.2%) 25.9% (23.8-28.1%) 1.00 (ref.) 1.00 (ref.)
0-30 g 4,175 63.9% (62.4-65.3%) 25.5% (23.9-27.1%) 0.98 (0.85-1.13) 0.97 (0.82-1.14)
>30 g 92 1.4% (1.1-1.8%) 23.2% (14.6-34.9%) 0.87 (0.48-1.55) 0.74 (0.40-1.39)
unknown 15
mean alcohol intake (g/d) 5.6 (5.3-5.8)
Underweight (BMI <20 kg/m2) p=0.8712 p=0.8712 p=0.0146
no 5,694 86.3% (85.2-87.4%) 25.7% (24.4-27.1%) 1.00 (ref.) 1.00 (ref.)
yes 892 13.7% (12.7-14.8%) 26.0% (22.7-29.7%) 1.02 (0.83-1.24) 1.34 (1.06-1.69)
unknown 139
mean BMI (kg/m2) 24.2 (24.0-24.3)
Physical activity p=0.1262 p=0.1286 p=0.0398
inactive 1,596 20.9% (19.8-22.2%) 27.5% (24.9-30.4%) 1.00 (ref.) 1.00 (ref.)
partially active 2,675 41.5% (40.0-43.0%) 24.2% (22.2-26.2%) 0.84 (0.70-1.00) 1.06 (0.86-1.30)
active 2,442 37.6% (36.1-39.1%) 26.2% (24.1-28.3%) 0.93 (0.78-1.11) 1.27 (1.03-1.56)
unknown 12
Falls in the past 12 monthsd p=0.0623 p=0.0625 p=0.0128
no 2,528 75.0% (73.2-76.8%) 38.9% (36.6-41.3%) 1.00 (ref.) 1.00 (ref.)
yes 892 25.0% (23.2-26.8%) 43.3% (39.4-47.4%) 1.20 (0.99-1.45) 1.30 (1.06-1.60)
unknown 3,305
a respondents, unweighted data.
b controlled for sociodemographic and socioeconomic factors (age, region and residential area, income, hospitalisation insurance type, and education level)
except language region was not controlled for region because of collinearity.
c information only available for women older than 40 years.
d information only available for women aged 60 years and older.
BDM ever performed in women aged 40 years and older living in Switzerland according to sociodemographic, socioeconomic, risk and healthcare- related factors
(SHS 2007 data).
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According to our analysis of the SHS 2007 data, lifetime
prevalence of BDM and current OM in women aged at
least 40 years was only 26% and 8%, respectively. These
prevalences seem low taking into account that BDM is
not only performed to screen but also to diagnose osteo-
porosis after a fracture occurred, and similarly that OM
is not only taken to cure but also to prevent osteopo-
rosis. This low coverage might indicate that the risk for
osteoporosis is not fully appreciated by physicians or thegeneral population in Switzerland. The public seems to
perceive osteoporosis as a minor health issue, for exam-
ple compared to cancer, although osteoporosis is estima-
ted to account for more disability-adjusted life-years lost
than most cancers, except lung cancer [26].
In Switzerland, healthcare services are in principle equally
accessible to all individuals, as the healthcare system is
publicly funded, and health insurance, being compulsory,
covers all residents equally. Nevertheless, we found dispa-
rities in the utilisation of BDM and OM with respect to
Table 2 OM in women according to sociodemographic, socioeconomic, and healthcare-related factors
Osteoporosis medication Samplea Population Proportion with OM Unadjusted model Adjusted modelb
HRT not included N % (95% CI) % (95% CI) crude OR (95% CI) adjusted OR (95% CI)
Total 6,836 100.0% 7.8% (7.0-8.6%)
Sociodemographic factors
Age group p=0.0000 p=0.0000 p=0.0000
40-49 years 1,645 29.3% (27.8-30.8%) 1.5% (0.9-2.5%) 0.27 (0.15-0.51) 0.22 (0.11-0.45)
50-59 years 1,586 25.3% (23.9-26.7%) 5.1% (3.9-6.8%) 1.00 (ref.) 1.00 (ref.)
60-69 years 1,667 21.5% (20.3-22.7%) 9.2% (7.7-11.0%) 1.87 (1.31-2.67) 1.93 (1.32-2.83)
70-79 years 1,258 15.4% (14.4-16.4%) 17.7% (15.1-20.6%) 3.96 (2.79-5.61) 4.07 (2.75-6.01)
≥80 years 680 8.6% (7.9-9.4%) 15.5% (12.4-19.2%) 3.38 (2.28-5.01) 3.53 (2.27-5.47)
mean age (years) 59.3 (58.9-59.7)
Nationality p=0.7348 p=0.6753 p=0.6460
Swiss citizen 5,565 76.7% (75.3-78.1%) 7.9% (7.1-8.8%) 1.00 (ref.) 1.00 (ref.)
Swiss dual citizen 721 10.0% (9.2-10.9%) 6.8% (5.0-9.4%) 0.85 (0.59-1.23) 1.09 (0.74-1.61)
others 548 13.3% (12.0-14.6%) 7.5% (5.0-11.0%) 0.94 (0.61-1.45) 1.28 (0.73-2.25)
unknown 2
Language region p=0.0452 p=0.0774 p=0.1380
German 4,179 72.3% (71.5-73.0%) 7.3% (6.4-8.3%) 1.00 (ref.) 1.00 (ref.)
French 2,034 22.6% (21.9-23.3%) 9.3% (7.9-11.0%) 1.31 (1.03-1.65) 1.22 (0.94-1.59)
Italian 623 5.1% (4.8-5.4%) 7.6% (5.5-10.4%) 1.05 (0.72-1.52) 0.84 (0.57-1.25)
Region p=0.0041 p=0.0067 p=0.0259
Lake Geneva 1,235 17.5% (16.9-18.2%) 8.9% (7.2-10.9%) 0.93 (0.68-1.28) 0.91 (0.64-1.30)
Midland 1,791 23.2% (22.5-24.0%) 9.5% (7.8-11.6%) 1.00 (ref.) 1.00 (ref.)
Northwest 762 14.8% (14.3-15.4%) 9.0% (7.0-11.6%) 0.95 (0.66-1.35) 0.97 (0.66-1.41)
Zurich 891 17.6% (16.9-18.3%) 5.9% (4.4-7.7%) 0.59 (0.41-0.86) 0.61 (0.41-0.92)
East 699 12.7% (12.1-13.2%) 6.0% (4.3-8.3%) 0.61 (0.40-0.92) 0.69 (0.44-1.06)
Central 842 9.3% (8.9-9.7%) 5.2% (3.6-7.5%) 0.52 (0.33-0.81) 0.52 (0.32-0.83)
Ticino 616 4.9% (4.7-5.2%) 7.9% (5.8-10.8%) 0.82 (0.55-1.24) 0.68 (0.44-1.06)
Residential area p=0.2792 p=0.2796 p=0.3755
urban 4,814 74.7% (73.5-75.9%) 8.0% (7.2-9.0%) 1.00 (ref.) 1.00 (ref.)
rural 2,022 25.3% (24.1-26.5%) 7.0% (5.6-8.7%) 0.86 (0.66-1.13) 0.87 (0.65-1.18)
Socioeconomic
factors
Education level p=0.0038 p=0.0044 p=0.5559
compulsory 1,562 21.1% (19.9-22.4%) 10.0% (8.2-12.2%) 1.00 (ref.) 1.00 (ref.)
secondary 4,109 61.3% (59.8-62.8%) 7.5% (6.5-8.5%) 0.72 (0.56-0.93) 0.85 (0.62-1.17)
tertiary 1,161 17.6% (16.5-18.8%) 5.9% (4.6-7.7%) 0.57 (0.40-0.81) 0.94 (0.62-1.45)
unknown 4
Income per capita p=0.9508 p=0.9579 p=0.8105
lower tertile 2,075 32.8% (31.4-34.4%) 7.8% (6.4-9.5%) 1.00 (ref.) 1.00 (ref.)
middle tertile 2,148 35.4% (33.9-37.0%) 7.5% (6.4-8.9%) 0.96 (0.72-1.28) 0.90 (0.67-1.23)
upper tertile 2,090 31.8% (30.3-33.2%) 7.5% (6.3-9.0%) 0.96 (0.72-1.29) 0.94 (0.67-1.32)
unknown 523
mean income (CHF per month) 3995 (3918-4072)
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Table 2 OM in women according to sociodemographic, socioeconomic, and healthcare-related factors (Continued)
Hospitalisation insurance p=0.0020 p=0.0026 p=0.0270
public 3,961 61.5% (60.0-63.0%) 6.7% (5.8-7.7%) 1.00 (ref.) 1.00 (ref.)
semiprivate 1,795 27.2% (25.9-28.6%) 9.1% (7.7-10.8%) 1.40 (1.10-1.79) 1.40 (1.07-1.84)
private 794 11.3% (10.4-12.3%) 10.3% (8.0-13.2%) 1.61 (1.17-2.22) 1.40 (0.98-1.98)
unknown 286
Healthcare-related
factors and medication
Bone density measurement p=0.0000 p=0.0000 p=0.0000
no 4,670 73.8% (72.5-75.1%) 2.2% (1.8-2.8%) 1.00 (ref.) 1.00 (ref.)
yes 1,858 26.2% (24.9-27.6%) 22.8% (20.6-25.3%) 13.03 (10.03-16.92) 9.87 (7.37-13.22)
unknown 308
Number of doctor
visits in the past 12 months p=0.0000 p=0.0000 p=0.0000
no visits 896 13.5% (12.5-14.7%) 2.9% (1.8-4.7%) 1.00 (ref.) 1.00 (ref.)
1 visit 1,333 21.6% (20.3-22.9%) 3.8% (2.8-5.2%) 1.31 (0.74-2.33) 1.78 (0.97-3.27)
2-6 visits 3,206 47.4% (45.8-48.9%) 8.4% (7.2-9.7%) 3.02 (1.83-5.01) 3.01 (1.75-5.16)
>6 visits 1,227 17.5% (16.4-18.7%) 13.8% (11.6-16.4%) 5.32 (3.16-8.94) 4.79 (2.74-8.39)
unknown 174
mean number of visits 4.7 (4.4-5.0)
Gynaecologist check-up
in the last 12 months p=0.3969 p=0.3971 p=0.0001
no 3,621 52.5% (50.9-54.0%) 7.8% (6.8-9.0%) 1.00 (ref.) 1.00 (ref.)
yes 3,017 47.5% (46.0-49.1%) 7.2% (6.2-8.3%) 0.91 (0.73-1.13) 1.61 (1.26-2.06)
unknown 198
Cancer screening
(breast, colon) ever
performed
p=0.0002 p=0.0002 p=0.4590
no 2,854 46.2% (44.7-47.8%) 6.0% (5.0-7.1%) 1.00 (ref.) 1.00 (ref.)
yes 3,740 53.8% (52.2-55.3%) 9.0% (8.0-10.1%) 1.56 (1.24-1.96) 1.10 (0.85-1.42)
unknown 242
Health-oriented
lifestyle
p=0.3006 p=0.3019 p=0.2900
no 374 7.2% (6.3-8.1%) 5.9% (3.7-9.2%) 1.00 (ref.) 1.00 (ref.)
yes 4,796 92.8% (91.9-93.7%) 7.5% (6.7-8.4%) 1.30 (0.79-2.15) 1.36 (0.77-2.42)
unknown 1,666
Self-assessed health
state
p=0.0000 p=0.0000 p=0.0000
(very) good 5,406 79.9% (78.6-81.1%) 5.9% (5.2-6.6%) 1.00 (ref.) 1.00 (ref.)
medium 1,080 15.2% (14.2-16.3%) 14.6% (12.1-17.4%) 2.74 (2.13-3.53) 2.02 (1.52-2.68)
(very) poor 347 4.9% (4.3-5.6%) 17.4% (12.3-24.2%) 3.40 (2.20-5.24) 2.89 (1.64-5.09)
unknown 3
a respondents, unweighted data.
b controlled for sociodemographic and socioeconomic factors (age, region, residential area, income, hospitalisation insurance type, and education level) except
language region was not controlled for region because of collinearity.
Taking prescribed OM in the last 7 days in women older than 40 years living in Switzerland according to sociodemographic, socioeconomic and healthcare-
related factors (SHS 2007 data).
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factors (Table 1, Table 2). Similar variations have previously
been documented for other curative and preventive health-
care services in Switzerland [20,27]. Inequalities in BDM
utilisation have also been observed in the US and in
Canada, despite existing recommendations for routine
BDM [9,11,12].
Sociodemographic, socioeconomic and healthcare-related
factors
Generally, the utilisation of preventive health care services
is lower among foreigners than among Swiss nationals
[20], although no differences were found for mam-
mography screening, regarding nationality [27,28]. Simi-
larly we found that BDM prevalence was comparable for
foreign and for Swiss women, but unexpectedly was
higher for Swiss dual citizens.
Consistent with general health service demand [20] and
particularly with mammography screening [27,29,30] in
Switzerland, also BDM and OM utilisation in women dif-
fered by region and/or language region. These disparities
may not only be caused by unequal needs or physician
recommendations, but also by differences in physician
density or, with respect to BDM, due to differences in the
density and/or distribution of DXA centres [31], and
therefore unequal access.
Also similar to the pattern found for the general use of
health services [20] and mammography screening [27]
our results showed that women with supplementary
private insurance in case of hospitalisation utilised BDM
and OM more often. This cannot be explained by the
fact that having private insurance is also correlated with
higher income and higher education level because we
controlled for both factors. But several other reasons
may account for this remarkable variation by type of
insurance. On the one hand, women′s demand e.g. due
to more worrying, their needs or the consent for BDM
or medication could differ. On the other hand, doctors’
provision of care, especially of BDM, may also have dif-
fered because compulsory health insurance does not
cover BDM for screening purposes, except for those with
certain major risk factors, whereas all the BDM for diag-
nostic purposes are reimbursed [10]. BDM screening is
to some extent covered for individuals who have an op-
tional health insurance supplement. In contrast to BDM,
reimbursement for OM is not dependent on health insu-
rance type but on having had a BDM: With the exception
of calcium, vitamin D, and some bisphosphonates, all
osteoporosis drugs are only reimbursed if the person has
BDM-diagnosed osteoporosis or has had a fracture [19].
Furthermore, consistent with the general demand [20]
but partially in contrast to mammography utilisation
[27,28] we found that BDM prevalence increased withincome and education level in women. Similarly, in
Canada higher income was directly associated with
higher BDM utilisation in women [14], whereas in the
US a similar disparity existed for screening but not for
diagnostic BDM [15]. It is unlikely that differences in
osteoporosis prevalence explain the observed variations
by socioeconomic status [32].
Similar to the findings for mammography screening in
Switzerland [27], our results clearly show that history of
BDM and taking OM increased by the intensity of
healthcare use in women, as quantified by the number
of doctor visits in the 12 months prior to the interview
or having had a gynaecologist check-up in the last 12
months. Likewise in the US, postmenopausal women
with diagnosed osteoporosis were more likely to receive
osteoporosis treatment when they had routine medical
care or when they had discussed the treatment with a
gynaecologist [18]. A higher healthcare use could obvi-
ously be the consequence of a poorer health state, or alter-
natively could result from a health-oriented but worrying
health behaviour independent from health state. However
increased anxiety in the absence of osteoporosis risk
factors does not seem to be associated with a reduced
bone density, and therefore would not constitute an indi-
cation for performing a BDM [33]. Our findings might
indicate an inappropriate BDM and OM utilisation in that
certain women have BDM or OM who do not meet the
indications, and others who are likely to meet the indi-
cations do not get it. BDM and OM should be targeted
according to established recommendations [34] to make
rational use of the healthcare budget and to properly
balance benefits and harms of BDM and OM [35].
The variation of BDM and OM utilisation by sociode-
mographic, socioeconomic and healthcare-related factors,
which possibly originate from variations in reimbursement
and in availability and utilisation of health services could
lead to a situation in which some women are underserved
or overtreated. This might foster further health inequa-
lities and therefore needs further investigation.
Osteoporosis risk factors
According to the SVGO recommendations [9], BDM is
indicated for women and men with at least one major or
two minor risk factors for osteoporosis or an osteoporotic
fracture. The major factors include being older than 70
years, being underweight and having pronounced physical
inactivity. The minor factors include smoking and exces-
sive alcohol consumption.
In Swiss resident women, all major but none of the
minor risk factors were associated with ever having had
a BDM. This may reflect the designated consideration of
the SVGO recommendations to decide who should have
a BDM, or it may also result from specific conditions
when BDM is covered by the health insurance [10].
Born and Zwahlen BMC Musculoskeletal Disorders 2013, 14:10 Page 11 of 12
http://www.biomedcentral.com/1471-2474/14/10Osteoporosis prevalence and estimated 10-year osteo-
porosis facture probability increase with age, i.e. probabi-
lity for women in Switzerland is 6% at age 50 but 33% at
age 85 [1]. Hence, an age-dependent increase of BDM and
OM utilisation were expected, but we found a slight
decrease for individuals aged 80 years and older compared
to those aged 70–79 years. This is inconsistent with the
SVGO recommendations as age is a major risk factor [36].
However, this old-age effect may result from selection
bias, as institutionalised women are not covered by the
SHS. Osteoporotic fractures are a major factor leading to
people having to enter a nursing home. [2,37-39]. It is
therefore likely that women with BDM-diagnosed osteo-
porosis and subsequent OM are more likely residing in
such institutions, which is especially true for the oldest.
Strengths and limitations
This study was based on the SHS data, which makes the
results representative for adult Swiss resident women.
The SHS data provide rich information on health-related
issues and on the sociodemographic and socioeconomic
characteristics of the respondents.
Although the participants were selected in a random
two-stage sampling process, selection bias cannot be
excluded, as only persons living in private households with
a landline phone could be surveyed. I.e., as institutionalised
Swiss residents were not covered by the SHS, this study
may have underestimated the population prevalence of
lifetime BDM and current OM [2,37]. Additionally, some
misclassification due to reporting and recall bias may have
occurred as the data were based on information self-
reported by the participants and therefore were dependent
on their understanding of the questionnaire, their recall
capacity and their willingness to respond accurately.
Either, BDM is used for osteoporosis screening, for
diagnosis after osteoporotic fractures, or to monitor med-
ical osteoporosis treatment. The SHS 2007 asked about
BDM history but not about motive for the most recently
performed BDM. Therefore, no differentiation between
BDM for screening, diagnosis, or monitoring was possible.
Similarly, for OM, it was not possible to distinguish treat-
ment for primary prevention of an osteoporotic fracture
and therapy for secondary prevention of further fractures.
Finally, the questionnaire included no questions on osteo-
porosis or osteoporotic fractures.
Conclusions
Our analysis of the SHS 2007 data describes for the first
time factors associated with BDM history and current
OM utilisation in Swiss women. The low BDM and OM
coverage might indicate that the risk of osteoporosis and
osteoporotic fractures is not fully appreciated by physi-
cians or the general population in Switzerland. BDM
and OM prevalence varied substantially according tohealthcare-related, sociodemographic, and socioecono-
mic factors, which might foster further health inequali-
ties. The reasons for these disparities and the low BDM
and OM prevalences should be investigated in further
studies of elderly Swiss women, including those living in
institutions.
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